FLT3 and cancer: Data indicated two levels of cellular targets of Vi7392 (3 μM) on the basis of a drug competition-reduced binding at a stringency of ≤10% (S10) for the kinases CDKL1 and PIP5K2C and, in addition, at a lower stringency of ≤35% (S35) for the kinases CDKL1, PIP5K2C, EGFR, MAPK2K5, MKNK2 and PRKG2 (note that cancer-specific kinase mutants of EGFR and FLT3, which do not have a known relevance for HCMV infection, were not further considered in this context).